Replies to post #111478 on Biotech Values

[microcapfun]

JAK/RA

>>Off-hand it looks to me like you're looking at old data.<<

Well ... yeah. I was comparing P2 Pfizer data to P2 Incyte data, rather than comparing P3 to P2.

But thanks for the P3 to P2 comparison. Pfizer's drug minus placebo ACR response rates are still higher for all of ACR20, ACR50 and ACR70, although I agree that only ACR20 looks like it might reach statistical significance.

But ACR was the primary endpoint.

micro